Brokerage Firm Rating Update on Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN) has an average broker rating of 2.39, which is interpreted as a Buy, as rated by 18 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 10 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Regeneron Pharmaceuticals (REGN) : The most positive equity analysts on Regeneron Pharmaceuticals (REGN) expects the shares to touch $668, whereas, the least positive believes that the stock will trade at $325 in the short term. The company is covered by 16 Wall Street Brokerage Firms. The average price target for shares are $474.56 with an expected fluctuation of $83.34 from the mean.


For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Baird downgrades the rating on Regeneron Pharmaceuticals (NASDAQ:REGN). The brokerage firm has issued a Neutral rating on the shares. The shares were previously rated Outperform. The rating by the firm was issued on August 5, 2016.

Regeneron Pharmaceuticals (NASDAQ:REGN): The stock opened at $397.72 and touched an intraday high of $401.76 on Wednesday. During the day, the stock corrected to an intraday low of $395.65, however, the bulls stepped in and pushed the price higher to close in the green at $399.89 with a gain of 0.40% for the day. The total traded volume for the day was 820,022. The stock had closed at $398.31 in the previous trading session.

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.